[Evaluation of intratherapeutic 177Lu-HA-DOTATATE treatment in neuroendocrine tumors: dosimetry with SPECT, whole-body imaging and gamma probe]
{{output}}
Aim: Peptide receptor radionuclide therapy (PRRT) with 177Lu-HA-DOTATATE has evolved as a new path in the treatment of somatostatin-receptor-expressing neuroendocrine tumors. The kidneys are proven as organs at risk and should b... ...
